| The US Pharmaceutical Market Outlook To 2014: | | | | and indications within cardiovascular, autoimmune, |
| Market trends, leading players and forecasts | | | | skin, CNS, and metabolic disorders. |
| Report Overview | | | | • Understand the latest developments within |
| The US pharmaceutical and biotech industry is | | | | the US healthcare system, including pricing and |
| currently facing a number of macroeconomic | | | | reimbursement, health insurance and regulatory |
| challenges and industry specific issues such as a | | | | issues, and identify how the healthcare reforms |
| slowed innovation process, a stringent FDA and | | | | of the new administration will affect the future of |
| significant patent losses in the near future. Large | | | | the pharma and biotech industries. |
| pharma companies are considering strategic | | | | • Forecast sales for key therapy/sub therapy |
| acquisitions and re-evaluating their business models | | | | areas and leading brands in the US pharma |
| in a bid for survival. President Obama's | | | | market over 2009-2014, identify key industry |
| administration has also planned extensive | | | | trends and events and evaluate leading companies |
| healthcare reforms that will involve significant | | | | and products within the US biotech market and |
| investments, in an attempt to revamp the | | | | generics industry. |
| healthcare landscape of the country. | | | | • Compare the franchises of major pharma |
| ‘The US Pharmaceutical Market Outlook to | | | | companies across key indications, with this |
| 2014' is a report published by Business Insights | | | | report's analysis of sales by drug class/leading |
| that provides comprehensive coverage of the US | | | | brands, pipeline focus and a strategic analysis for |
| pharma market, incorporating the market | | | | Amgen, Gilead, GSK, J&J, Pfizer, |
| structure, pricing and regulation, in addition to | | | | Roche-Genentech, Sandoz, Teva-Barr. |
| detailed analysis of leading companies and potential | | | | Key issues |
| healthcare reforms. This report assesses the | | | | Healthcare reforms to halt rising costs. The new |
| marketed product portfolios, R&D pipelines, | | | | administration is driving healthcare reforms with |
| market share data, sales forecasts and | | | | savings to be generated from measures including |
| competitive landscape of the major players in the | | | | disease prevention and the implementation of |
| US market. It highlights the key market and | | | | electronic medical records. Other potential |
| R&D trends that may influence treatment | | | | strategies being considered are Medicare pricing |
| sales with a thorough analysis of the competitive | | | | reform, universal healthcare, increased Medicaid |
| dynamics of leading brands within each indication. | | | | rebates, a comparative effectiveness institute and |
| This report also identifies growth trends and | | | | a new pathway for biosimilar approval. |
| developments for key drug classes and leading | | | | Greater FDA stringency. Growing political pressure |
| players through to 2014. | | | | and criticism over drug safety issues in the past |
| Key Findings | | | | have led to the FDA becoming increasingly vigilant, |
| The US pharmaceutical market recorded sales of | | | | resulting in fewer drugs being approved. The |
| $279bn in 2007, a 3.9% increase over 2006. The | | | | agency is currently suffering from a lack of funds |
| top 10 brands of the US market represented | | | | and expert staff. |
| 14.4% of total market value in 2007. | | | | SIgnificant patent losses ahead. The US pharma |
| CNS disorders constitute the leading therapeutic | | | | industry is facing a wave of patent expirations |
| category of the US pharma market, with sales of | | | | over the forecast period. Key expirations through |
| $60.2bn and a market share of 21.6% in 2007. | | | | 2012 include the cholesterol-lowering drug Lipitor, |
| This is followed by CVD treatments, which | | | | platelet drug Plavix, antipsychotic Zyprexa, |
| amassed sales worth $38.2bn and a market share | | | | antidepressant Effexor, and asthma drug Singulair. |
| of 13.7% in 2007. | | | | Almost every major company will lose patent |
| Pfizer was the leading player in the US pharma | | | | protection on their largest products over the |
| market in 2007, with sales of $22.5bn, a decline of | | | | forecast period. |
| 12.3% over 2006. This was largely due to a drop | | | | Discover... |
| in sales posted by its leading brand Lipitor. | | | | • What will be the major growth drivers in the |
| Pharma companies are focusing on acquisitions of | | | | US pharma market over 2009-14? |
| smaller biotech firms to strengthen their drug | | | | • Which companies were the winners and |
| pipelines. This tactic is also being pursued to | | | | losers in the US pharma market in 2007? |
| diversify portfolios with an array of market | | | | • What are the key strengths of the leading |
| offerings, in an effort to lessen the impact of | | | | pharmaceutical, biotechnology and generic |
| poor performance within individual therapy areas | | | | companies? |
| or industry segments. | | | | • Which products will be affected by generic |
| The US biotech industry saw high growth from | | | | competitors over the period 2009-14? |
| key players such as Gilead Sciences, which posted | | | | • Which pipeline products will be the growth |
| a growth rate of 54.2% between 2006-07. This | | | | drivers of the future? |
| was primarily driven by sales from its HIV | | | | • Which therapy areas and indications are |
| franchise, which includes Atripla, Truvada and its | | | | forecast to have significant commercial prospects |
| Hepatitis B drugs. | | | | over the period 2009-14? |
| Use this report to... | | | | • How will the US pharma market's |
| • Examine the forecast prevalence of major | | | | competitive landscape change by 2014? |
| diseases in the US pharma market over 2008-14 | | | | • What are the key healthcare reforms being |
| with this report's analysis of various cancer types | | | | considered by the new administration? |